Carlyle buys a small piece of Shenzhen Salubris
Global asset management company Carlyle Group has taken a minority stake in Shenzhen Salubris Pharmaceuticals. The U.S.-based private equity firm has agreed to invest $260 million in the Shenzhen-listed drug company, representing a 5% stake in the business.
Carlyle will help accelerate Salubris’s innovative drug development, lending its industry expertise, network and resources to drive global and domestic expansion through organic growth as well as M&A, Carlyle said in a statement.
Founded in 1998, Salubris manufactures and sells a range of generic medicines covering diabetes, cardiovascular diseases, and infections, as well as medical devices. The company also engages in R&D in biologics and gene therapies in the areas of cardio- and cerebrovascular diseases, metabolic disease, and oncology.
Salubris is chaired by Chinese billionaire Ye Chenghai, a former mayor of Shenzhen. Ye’s son is the current CEO of the company.
Carlyle will help accelerate Salubris’s innovative drug development, lending its industry expertise, network and resources to drive global and domestic expansion through organic growth as well as M&A, Carlyle said in a statement.
Founded in 1998, Salubris manufactures and sells a range of generic medicines covering diabetes, cardiovascular diseases, and infections, as well as medical devices. The company also engages in R&D in biologics and gene therapies in the areas of cardio- and cerebrovascular diseases, metabolic disease, and oncology.
Salubris is chaired by Chinese billionaire Ye Chenghai, a former mayor of Shenzhen. Ye’s son is the current CEO of the company.
.png)
No hay comentarios:
Publicar un comentario